Literature DB >> 1674242

Pharmacokinetic interactions between theophylline and other medication (Part I).

R A Upton1.   

Abstract

Many drugs have been found to increase or decrease the clearance of theophylline, probably by interaction with one or more of the variants of the cytochrome P450 drug-metabolising system. Theophylline may be particularly susceptible to alteration of its clearance because of the particular form(s) of the P450 system involved, because its metabolism is saturable, and/or because 90% of its elimination is via metabolism. Its clearance has been found to be decreased (typically by around 25%, but often by far more) by erythromycin, troleandomycin (triacetyloleandomycin), roxithromycin, enoxacin, ciprofloxacin, pefloxacin, norfloxacin, ofloxacin, fluoroquinolone T-3262, pipemidic acid, cimetidine, etintidine, propranolol, verapamil, diltiazem, nifedipine, furosemide (frusemide), at least some anovulent agents, viloxazine, allopurinol, ticlopidine, idrocilamide, thiabendazole, disulfiram, influenza- and BCG-vaccination, interferon, and caffeine (half-life increase). In contrast, theophylline clearance (clearance/bioavailability) was found to be increased by isoprenaline (isoproterenol), terbutaline, some corticosteroids, phenytoin, phenobarbital, activated charcoal, felodipine moricizine, benzodiazepines and sulfinpyrazone - typically by about 25%, but sometimes by as much as 80% or more. For several of these concomitant medications, however, only some of the published studies can substantiate an influence, which may highlight the sensitivity of some interactions to particular experimental and/or clinical conditions, e.g. with terbutaline, erythromycin, ciprofloxacin, norfloxacin, ofloxacin, phenobarbital, cimetidine, verapamil, diltiazem, nifedipine, anovulents, allopurinol and influenza vaccination. Moreover, reports both of inhibition and of induction of theophylline clearance by each of rifampicin and isoniazid have appeared. Nevertheless, under investigation many medications have not been found to perceptibly influence theophylline disposition kinetics, e.g. ephedrine, orciprenaline (metaproterenol), prednisone, prednisolone, temelastine, terfenadine, mequitazine, picumast, repirinast, josamycin, midecamycin, miocamycin, spiramycin, amoxicillin, ampicillin, cefalexin, cefaclor, ceftibuten, cotrimoxazole (trimethoprim plus sulfamethoxazole), tetracycline, doxycycline, lomefloxacin, fluoroquinolones NY-198 and AM-833, nalidixic acid, lincomycin, metronidazole, certain antacids, ranitidine, roxatidine, pirenzepine, rioprostil, metoclopramide, metoprolol, atenolol, nadolol, medroxyprogesterone, dextropropoxyphene (propoxyphene), piroxicam, ozagrel, mebendazole and ascorbic acid.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1674242     DOI: 10.2165/00003088-199120010-00005

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  16 in total

Review 1.  Metabolism of some "second"- and "fourth"-generation antidepressants: iprindole, viloxazine, bupropion, mianserin, maprotiline, trazodone, nefazodone, and venlafaxine.

Authors:  S Rotzinger; M Bourin; Y Akimoto; R T Coutts; G B Baker
Journal:  Cell Mol Neurobiol       Date:  1999-08       Impact factor: 5.046

Review 2.  Formulary management of macrolide antibiotics.

Authors:  D R Guay
Journal:  Pharmacoeconomics       Date:  1995-12       Impact factor: 4.981

3.  Development of a new quantitative approach for the isobolographic assessment of the convulsant interaction between pefloxacin and theophylline in rats.

Authors:  L M Levasseur; A Delon; W R Greco; P Faury; S Bouquet; W Couet
Journal:  Pharm Res       Date:  1998-07       Impact factor: 4.200

Review 4.  Clinical pharmacology of Cilomilast.

Authors:  Geoff Down; Sarah Siederer; Sam Lim; Peter Daley-Yates
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

5.  The quinolone, flumequine, has no effect on theophylline pharmacokinetics.

Authors:  B Lacarelle; O Blin; C Audebert; P Auquier; H Karsenty; F Horriere; A Durand
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

Review 6.  Fleroxacin clinical pharmacokinetics.

Authors:  A E Stuck; D K Kim; F J Frey
Journal:  Clin Pharmacokinet       Date:  1992-02       Impact factor: 6.447

7.  Metabolism of theophylline by cDNA-expressed human cytochromes P-450.

Authors:  H R Ha; J Chen; A U Freiburghaus; F Follath
Journal:  Br J Clin Pharmacol       Date:  1995-03       Impact factor: 4.335

8.  Treatment of chronic obstructive pulmonary disease in hospitalized geriatric patients.

Authors:  J Schlitzer; S Haubaum; H Frohnhofen
Journal:  Z Gerontol Geriatr       Date:  2014-06       Impact factor: 1.281

Review 9.  Drug interactions with quinolone antibacterials.

Authors:  J R Brouwers
Journal:  Drug Saf       Date:  1992 Jul-Aug       Impact factor: 5.606

Review 10.  Pharmacokinetic optimisation of asthma treatment.

Authors:  A M Taburet; B Schmit
Journal:  Clin Pharmacokinet       Date:  1994-05       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.